Pfizer Inc. (NYSE:PFE) Shares Bought by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.5% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 146,269 shares of the biopharmaceutical company’s stock after purchasing an additional 12,645 shares during the period. Pfizer makes up approximately 1.8% of Murphy Pohlad Asset Management LLC’s portfolio, making the stock its 15th biggest holding. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $4,233,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Marshall Wace LLP grew its position in Pfizer by 279.3% during the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the period. Swedbank AB acquired a new stake in shares of Pfizer during the 1st quarter valued at about $172,902,000. International Assets Investment Management LLC acquired a new stake in shares of Pfizer during the 3rd quarter valued at about $146,481,000. Pzena Investment Management LLC grew its position in shares of Pfizer by 181.6% during the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after acquiring an additional 4,947,000 shares during the period. Finally, 1832 Asset Management L.P. grew its position in shares of Pfizer by 24,961.6% during the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock valued at $69,891,000 after acquiring an additional 2,487,919 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Pfizer Stock Down 0.8 %

Pfizer stock opened at $28.08 on Friday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a 50 day moving average price of $29.03 and a 200 day moving average price of $28.57. The company has a market capitalization of $159.12 billion, a PE ratio of 37.95, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter last year, the firm earned ($0.17) EPS. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.98%. Pfizer’s payout ratio is currently 227.03%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday. Sanford C. Bernstein began coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Wells Fargo & Company raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, UBS Group raised their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.